The combination of ADCs with PD-1 inhibitors appears to be a feasible approach for inoperable HER2-positive or low-expressive breast cancer to improve the efficacy and survival outcome; however, this is awaiting confirmation by further large-population clinical trials (33). The gene discussed is ERBB2; the disease is breast cancer.